Study of Magrolimab Combinations in Participants With Myeloid Malignancies
Public ClinicalTrials.gov record NCT04778410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Myeloid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab (Mag), in combination with anti-leukemia therapies in participants with acute myeloid leukemia (AML).
Study identification
- NCT ID
- NCT04778410
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Interventions
- Magrolimab Drug
- Azacitidine Drug
- Venetoclax Drug
- Mitoxantrone Drug
- Etoposide Drug
- Cytarabine Drug
- CC-486 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2021 (Actual)
- Primary completion
- Mar 4, 2024 (Actual)
- Completion
- Mar 4, 2024 (Actual)
- Last update posted
- Mar 20, 2025
2021 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 13
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35233 | — |
| City of Hope (City of Hope National Medical Center, City of Hope Medical Center) | Duarte | California | 91010 | — |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California | 90048 | — |
| Stanford Cancer Center | Palo Alto | California | 94305 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| The University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| OU Health, Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04778410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04778410 live on ClinicalTrials.gov.